[{"id":"0e9471d7-43e2-4e80-ac84-cb6ec9ea52b4","acronym":"HERNEBC","url":"https://clinicaltrials.gov/study/NCT02806817","created_at":"2021-01-18T13:45:57.833Z","updated_at":"2024-07-02T16:36:57.785Z","phase":"Phase 1","brief_title":"ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism","source_id_and_acronym":"NCT02806817 - HERNEBC","lead_sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","biomarkers":" HER-2 • CASP3","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • ME-344"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 10/01/2018","primary_completion_date":" 10/01/2018","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2019-07-23"}]